Background/Aims: The Alzheimer's Disease Sequencing Project (ADSP) aims to identify novel genes influencing Alzheimer's disease (AD). Variants within genes known to cause dementias other than AD have previously been associated with AD risk. We describe evidence of co-segregation and associations between variants in dementia genes and clinically diagnosed AD within the ADSP. Methods: We summarize the properties of known pathogenic variants within dementia genes, describe the co-segregation of variants annotated as "pathogenic" in ClinVar and new candidates observed in ADSP families, and test for associations between rare variants in dementia genes in the ADSP case-control study. The participants were clinically evaluated for AD, and they represent European, Caribbean Hispanic, and isolate Dutch populations. Results/Conclusions: Pathogenic variants in dementia genes were predominantly rare and conserved coding changes. Pathogenic variants within ARSA, CSF1R, and GRN were observed, and candidate variants in GRN and CHMP2B were nominated in ADSP families. An independent case-control study provided evidence of an association between variants in TREM2, APOE, ARSA, CSF1R, PSEN1, and MAPT and risk of AD. Variants in genes which cause dementing disorders may influence the clinical diagnosis of AD in a small proportion of cases within the ADSP.
in dementia genes and define criteria for prioritizing candidate variants. We identify these variants, and candidate variants sharing their characteristics, in families sequenced by the ADSP. Finally, we summarize the evidence of an association between AD and variants within dementia genes from the ADSP case-control study. The results suggest that variants within genes causing dementias distinct from AD may yet play a role in clinically diagnosed AD.
Subjects and Methods

Subjects and Samples
The ADSP The ADSP has generated whole genome sequencing (WGS) data from members of multiplex AD families and whole exome sequencing (WES) data for a large case-control cohort [42] . Briefly, WGS data were collected on 582 individuals from 111 multiplex AD families of European or Caribbean Hispanic ancestry, favoring Chr., chromosome; Start, gene start position in build hg19/GRCh37 coordinates; End, gene end position in build hg19/GRCh37 coordinates; MIM, Mendelian Inheritance in Man identifier.
Center for Precision Diagnostics Sample
The Center for Precision Diagnostics (CPD) at the University of Washington provided targeted sequencing data for 48 neuropathologically confirmed controls with self-reported European ancestry (50% female). The 48 controls represent cognitively normal elderly adults enrolled in AD centers who did not meet neuropathological criteria for AD or Parkinson's disease upon their death at the age of ≥54 years [64] . The CPD used a targeted capture approach to sequence a panel of genes known to cause neurodegenerative disorders, including the dementia panel listed in Table 1 (disorders named in online Supplemental Table 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000485503), with > 99% of the targeted coding regions and canonical splice sites sequenced to > 20× coverage. Current information about this panel and the sequencing methods is available online (http://uwcpdx.org/neurodegenerative-panel/). DNA fragments were captured using the Exome v1.0 (Integrated DNA Technologies) system, paired-end sequencing was performed using Illumina technologies, including the Rapid Run v2.0 chemistry and a HiSeq 2500 sequencer. Reads were aligned to the hg19 reference genome using the BWA, and variant calling was performed with the GATK. This research was approved by the Veterans Affairs Puget Sound institutional review board (MIRB #00088).
Analysis Methods
We focused our analyses on the 35 genes listed in Table 1 , which represent the dementia gene panel provided by the CPD, a CLIA-certified laboratory for diagnostic genetic testing. Variants within these genes were downloaded from ClinVar (December 22, 2015) and converted from build GRCh38 sequence positions to GRCh37 using the LiftOver tool from the UCSC Genome Browser [65, 66] . We restricted the analyses to "consequential" variants, i.e., those annotated as pathogenic, likely pathogenic, risk variant, or protective in ClinVar, and used their reported consequences (e.g., missense). Consequential variants observed in the ADSP were evaluated by literature review on a variant-by-variant basis, including the AD & FTD Mutation Database [67] (www.molgen.ua.ac.be/admutations/), Online Mendelian Inheritance in Man [68, 69] 
Results
Characteristics of Known Consequential SNVs in Dementia Genes
The consequential SNVs in dementia genes reported in ClinVar were overwhelmingly rare missense variants with evidence of conservation and predicted pathogenicity. Although start/stop and splice site variants were represented ( Fig. 1) , all reported consequential SNVs in 9 dementia genes were missense: EIF2B3, EIF2B5, MAPT, PDGFB, PDGFRB, PSEN1, PSEN2, SLC25A12, and VCP. In contrast, most of the consequential SNVs in GRN were either start/stop or splice site variants. Most consequential SNVs reported in ClinVar were rare, with 492/496 (99.2%) of the SNVs with MAFs < 0.001 in independent reference populations. Among the 64 consequential SNVs observed in the reference data sets, 60 had MAFs < 0.001. Three of the remaining 4 SNVs were in APOE: rs7412 and rs429358 define the ε2 and ε4 alleles provided Black, all consequential variants in the 1000 Genomes Project; dark gray, consequential variants in the 1000 Genomes Project with a minor allele frequency < 0.001 in the 1000 Genomes, Exome Sequencing Project, and Exome Aggregation Consortium data sets; white, consequential variants reported in ClinVar; light gray, consequential variants in Center for Precision Diagnostics controls. by the ADSP contributors and are associated with protection or risk of AD [80] , while rs769455 had an MAF < 1% in reference populations and was observed 4 times as often in EuropeanAmerican AD cases versus controls [80] . Homozygotes for the remaining variant, rs5848 (MAF = 0.42 in the 1000 Genomes Project), have an increased risk of both FTD [81] and AD [82] .
Most consequential SNVs reported to ClinVar within the dementia genes were predicted to be pathogenic or conserved, unlike the SNVs observed in the reference or control data sets (Fig. 2) . Where annotation was available, the observed distribution of CADD and GERP scores better discriminated between the consequential ClinVar variants and the reference data sets (Fig. 2 ). Most consequential SNVs had high GERP or CADD scores: 91% of the consequential SNVs had GERP scores ≥3, and 84% had CADD scores (Phred scaled) ≥15.
Pathogenic ClinVar SNVs Observed in the ADSP Family WGS Data
Within the ADSP family WGS data, 7 SNVs within 6 dementia genes were annotated as pathogenic in ClinVar ( Table 2) . Four of the SNVs cause recessive disorders, but they were only observed in heterozygotes (rs28940893, rs80358257, rs113994049, and rs147313927) and are therefore unlikely to cause their corresponding dementias in these heterozygotes. The remaining 3 SNVs in GRN, CSF1R, and ARSA could potentially influence the dementia phenotype in their carriers. Dominant variants in GRN cause FTD (Table 1) . However, the homozygous alternate genotype at GRN variant rs5848 is associated with an increased risk of both FTD (OR = 3.18) [81] and AD (OR = 1.31 [82] and 1.386 [83] ). Within the ADSP WGS data, 65 homozygotes (45 cases) were observed within the 35 families. These subjects met the clinical criteria for either probable or definite AD, and are therefore not likely to have FTD, although comprehensive imaging data for these subjects are not available to formally exclude FTD pathology.
Dominant variants in CSF1R cause hereditary diffuse leukoencephalopathy with spheroids (MIM: 221820), a type of dementia which can mimic AD [84] (Table 1) . A pathogenic [84, 85] SNV in CSF1R, rs281860278, was observed in a member of family UM0304F diagnosed with probable AD at the age of 72 years. However, rs281860278 does not segregate with dementia in this family; this SNV was not observed in the carrier's sequenced relatives, including a sibling diagnosed with definite AD at the age of 73 years, a sibling diagnosed with probable Alternate allele frequencies are provided for the entire Alzheimer's Disease Sequencing Project whole genome sequencing data (ADSP WGS ), the 1000 Genomes reference data set (1KG), the NHLBI GO Exome Sequencing Project (ESP), and the Exome Aggregation Consortium (ExAC). Alternate allele carrier counts are provided for those in the ADSP WGS by their status (cases = probable or possible AD; unaffected = unaffected or at risk of AD), and the number of families carrying the alternate allele. Variants with PolyPhen-2 scores ≥0.957, SIFT scores <0.05, or Phred-scaled CADD scores ≥15 were predicted to be deleterious/pathogenic, while those with GERP scores ≥3 were considered conserved. AD, Alzheimer's disease; SNVs, single nucleotide variants; Tier, variant annotated as consequential in ClinVar or a new candidate variant; Alt., alternate allele; CADD, Phred-scaled Combined Annotation Dependent Depletion score; GERP, Genomic Evolutionary Rate Profiling score.
AD at the age of 75 years, and a niece at risk of AD at the age of 55 years. External sequencing data revealed that the SNV was observed in 2 additional siblings who were not clinically diagnosed with AD at the time of their deaths at the ages of 91 and 94 years.
The homozygous genotypes for each of 2 SNVs, rs6151429 (Table 2) and ARSA missense variant rs2071421 [86] , lead to arylsulfatase A pseudodeficiency [86] [87] [88] [89] , which can cause metachromatic leukodystrophy (MIM: 250100) if inherited with another ARSA missense variant [90, 91] . Homozygotes for both rs6151429 and rs2071421 were observed in 3 ADSP families (CU0044F, CU0049F, and NC0205F), although none carried an additional ARSA missense variant. WGS data were available for 11 individuals diagnosed with probable AD and 1 individual at risk of AD within family CU0044F. Within family CU0044F, 2 siblings diagnosed with probable AD at the ages of 71 and 86 years were homozygous for both rs6151429 and rs2071421. These 2 siblings are the offspring of a consanguineous marriage between avuncular relatives, suggesting they inherited both copies of the ARSA SNVs identical by descent. External sequencing data revealed that 0/3 additional at-risk members of CU0044F were homozygous for rs6151429 and rs2071421. WGS data were available for 6 individuals diagnosed with probable AD and 1 at-risk individual in family CU0049F. The only individual homozygous for both rs6151429 and rs2071421 from family CU0049F was the individual at risk of developing AD at the age of 60 years. This at-risk individual is the offspring of parents who were diagnosed with probable AD, with no sequencing data available. Within family NC0205F, WGS data were available for 1 individual diagnosed with definite AD, 1 diagnosed with probable AD, 1 diagnosed with possible AD, and 1 individual with an unknown phenotype. The 2 homozygotes observed in family NC0205F include a subject diagnosed with definite AD at the age of 75 years and a sibling diagnosed with possible AD at the age of 80 years, but not their cousins at risk of AD or diagnosed with possible AD at the age of 70 years. Most homozygotes for the 2 ARSA SNVs were clinically diagnosed with AD, but they do not represent all relatives diagnosed with AD within their families. External autopsy and imaging data were unavailable for any individual homozygous for both rs6151429 and rs2071421.
Rare SNVs Observed in the ADSP Family WGS Data That Share Properties with Consequential ClinVar SNVs
Two SNVs in the ADSP WGS family data share characteristics with known pathogenic variants in the dementia genes: a reference MAF < 0.001, a CADD score (Phred scaled) ≥15, and a GERP score ≥3 ( Table 2 ). The GRN missense SNV rs141111290 has previously been associated with AD [34] and is observed in ADSP families CU0012F and CU0042F. Within family CU0012F, rs141111290 carriers include a subject diagnosed with probable AD at the age of 73 years and a sibling diagnosed with possible AD at the age of 58 years, but not their siblings diagnosed with probable AD at the ages of 61 and 63 years. Within family CU0042F, the rs141111290 heterozygote was at risk of AD as of the age of 69 years, but the SNV was not observed in their sequenced relatives diagnosed with either probable (age 86 and 91 years) or possible (age 73 years) AD. In contrast, the CHMP2B SNV rs149380040 was observed in both sequenced cases from family CU0021F, diagnosed with probable AD at the ages of 77 and 83 years. This SNV causes a p.Ser194Leu change in the canonical transcript of CHMP2B and falls outside the conserved snf7 domain containing variants thought to cause FTD [92] . Although other variants in CHMP2B cause FTD, the ADSP cases carrying the p.Ser194Leu variant met the clinical criteria for probable AD and did not show clinical evidence of FTD.
Gene-Based Association Testing in the ADSP Case-Control Exome Data
Gene-based tests of rare variants revealed evidence of an association between 6 dementia genes (APOE, ARSA, CSF1R, MAPT, PSEN1, and TREM2) and risk of AD in the ADSP case-control analysis (p < 0.05; Table 3 ). TREM2 was significantly associated with AD under model 0 after
Discussion
We provided evidence that SNVs within AD genes (APOE [93] , PSEN1 [2, 94] , and TREM2 [16, 17, 95] ), genes causing dementias which may mimic AD (MAPT [12] [13] [14] [23] [24] [25] and CSF1R [96] [97] [98] [99] ), and a gene causing distinct dementias (ARSA) possibly influence the phenotype for a small number of cases of AD in the ADSP. Detailed phenotype and pathologic data are necessary to determine what role, if any, these SNVs play in AD, which are unavailable for most carriers of these SNVs in the ADSP data set. However, a few of these SNVs have strong evidence in the literature supporting their pathogenic role in dementia, including rs5848 in GRN [82, 83] and rs141111290 in CHMP2B [34] , which have previously demonstrated strong statistical associations with the risk of AD.
Among the genes causing non-AD dementias, pathogenic SNVs in both ARSA and CSF1R were observed in the family-based ADSP WGS data set and gene-based association testing in the large case-control cohort. CSF1R is differentially expressed in mouse models of AD [100, 101] and surrounding Aβ plaques in human cases of AD [102] . Inhibiting CSF1R in mouse models of AD ameliorates memory loss and synaptic degeneration [103] . That inhibition can be done pharmacologically [103] , suggesting CSF1R may be a promising drug target for AD. The connection between ARSA and AD is more tenuous. ARSA is downregulated in sex-specific analyses of cells derived from sporadic AD patients [104] . Furthermore, the pathogenic SNV observed in the ADSP WGS data set, rs6151429, was observed in 34% of postmortem brain samples from AD cases, which is much higher than the frequency in related populations [105] . These findings are intriguing, though the potential relationship between ARSA and AD requires further study before conclusions may be drawn.
Descriptive analyses of consequential SNVs in ClinVar have revealed several patterns which may help identify novel variants driving dementing disorders in these genes. Our results suggest that coding changes in dementia genes with low frequencies (MAF < 0.001) in reference populations and high CADD and/or GERP scores should be prioritized when nominating candidate variants for these disorders. Strict application of these filters to the ADSP WGS data prioritized an additional missense variant in GRN previously associated with AD risk [34] and a missense variant in CHMP2B observed in both sequenced cases diagnosed with probable AD in a single pedigree. Further analysis of each of these SNVs is required to evaluate their potential contribution to AD risk.
Variants in known dementia genes do not appear to explain the AD phenotype in the majority of the ADSP. However, rare pathogenic SNVs, or those sharing similar properties, may influence the phenotype in 1% of the subjects within the ADSP family WGS data set diagnosed with either definite or probable AD; this percentage increases to 11% when the common GRN risk variant is included. Where observed, SNVs annotated as "pathogenic" by ClinVar in known dementia genes would explain no more than half of the AD cases in a single family, consistent with the known genetic heterogeneity of AD [5, 94] . This suggests that novel AD genes remain to be uncovered in the ADSP sequence data set. For the Hispanic data: data collection for this project was supported by the Genetic Studies of Alzheimer's Disease in Caribbean Hispanics (EFIGA) funded by the National Institute on Aging (NIA) and by the NIH (5R37AG015473 and RF1AG015473). We acknowledge the EFIGA study participants and the EFIGA research and support staff for their contributions to this study.
The ADSP is composed of two AD genetics consortia and three National Human Genome Research Institute (NHGRI)-funded Large Scale Sequencing and Analysis Centers (LSACs). The two AD genetics consortia are the ADGC, funded by NIA U01 AG032984, and the CHARGE consortium, funded by NIA R01 AG033193, the National Heart, Lung, and Blood Institute (NHLBI), other NIH institutes, and other foreign governmental and nongovernmental organizations. The Discovery Phase analysis of the sequencing data is supported through UF1AG047133 (to Drs. The CHARGE cohorts, with funding provided through 5RC2HL102419 and HL105756, include the following: the Atherosclerosis Risk in Communities (ARIC) Study, which is carried out as a collaborative study supported by NHLBI contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C), the Austrian Stroke Prevention Study (ASPS), the Cardiovascular Health Study (CHS), the Erasmus Rucphen Family Study (ERF), the Framingham Heart Study (FHS), and the Rotterdam Study (RS). CHS research was supported through contracts HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086, as well as through grants U01HL080295 and U01HL130114 from the NHLBI, with an additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629, R01AG15928, and R01AG20098 from the NIA. A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
The three LSACs are: the Human Genome Sequencing Center at the Baylor College of Medicine (U54 HG003273), the Broad Institute Genome Center (U54HG003067), and the Washington University Genome Institute (U54HG003079).
The biological samples and associated phenotypic data used in primary data analyses were stored at the study investigators' institutions, and at the NCRAD (U24AG021886) at Indiana University, funded by the NIA. The associated phenotypic data used in the primary and secondary data analyses were provided by the study investigators, the NIA-funded ADCs, and the National Alzheimer's Coordinating Center (NACC; U01AG016976) and National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site (NIAGADS; U24AG041689) at the University of Pennsylvania, funded by the NIA, as well as at the dbGaP funded by the NIH. This research was supported in part by the Intramural Research Program of the NIH, National Library of Medicine. Contributors to the genetic analysis data included study investigators on projects that were individually funded by the NIA and other NIH institutes, as well as by private US organizations or foreign governmental or nongovernmental organizations.
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